Answers are grounded in this paper and cite their sources.
Background: Although endoscopic pancreatic duct stent placement is not currently recommended as a routine treatment in clinical guidelines for acute pancreatitis (AP), our institution has accumulated extensive clinical experience with this procedure, having treated over 2,000 patients to date. While previous clinical practice and studies by our team have established the efficacy and safety of this intervention, its impact on patient-reported outcomes (PROs) remains largely uncharacterized. To further establish a comprehensive evidence chain for this practice from multidimensional perspectives, this study aimed to describe the characteristics of PROs in patients with AP receiving pancreatic duct stents during their recovery, thereby evaluating its influence on patients' subjective rehabilitation. Methods: We conducted a single-center, longitudinal observational study of 146 patients with AP who underwent endoscopic pancreatic duct stent placement between October 2025 and April 2026. The clinical decision for stenting was individualized, based on the presence of prominent abdominal pain/distension, marked peripancreatic fluid exudation on contrast-enhanced CT, and significant elevation of inflammatory markers. All procedures were performed by a single senior endoscopist. PROs were assessed using the adapted Pancreatitis Quality of Life Instrument (PANQOLI) and the General Comfort Questionnaire (GCQ) at admission, before discharge, and 2 weeks post-discharge. Results: Among the 146 patients (biliary AP: 42.5%; hypertriglyceridemic AP: 38.4%), no procedure-related adverse events (e.g., bleeding, perforation, or exacerbation of pancreatitis) were observed. Mean PANQOLI total scores increased from 19.84 ± 3.92 at admission to 68.04 ± 2.93 before discharge, and 82.23 ± 2.35 at 2 weeks post-discharge. Similarly, mean GCQ scores improved significantly from 57.82 ± 3.35 to 93.51 ± 3.31 and 103.55 ± 2.42, respectively (P<0.001 for time effects). Notably, changes in objective laboratory inflammatory markers showed weak correlations with the trajectory of these subjective PRO scores. Conclusion: In this cohort study, patients with AP who underwent pancreatic duct stent placement demonstrated significant short-term improvements in quality of life and comfort, with no procedure-related adverse events observed. The divergence between subjective improvement and objective inflammatory markers highlights the value of incorporating patient-reported outcomes (PROs) into efficacy assessment frameworks. These exploratory findings provide a supplementary dimension of evidence for this off-guideline practice; however, further confirmation through future controlled studies is warranted.
No takes yet. Share an insight, caveat, or question.
姚艳绒 et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: